Partial D, Weak D, and RhD Genotyping: When to Go Beyond Serology

Myth: If someone types as Rh-D-positive, they can't make anti-D antibodies

At first glance, RhD typing seems straightforward: you’re either positive or negative. In reality, not all “RhD-positive” results are equal and this oversimplification can have serious consequences. Individuals with variant RhD phenotypes, particularly certain partial D and weak D types, may be mistakenly assumed to be “safe” from anti-D alloimmunization. In truth, many of them are at risk of developing anti-D if exposed to red cells expressing the full D antigen.

Let's Clarify the Terminology

Weak D ‘type’ refers to reduced expression of the D antigen on red cells, often due to mutations that affect protein quantity. These cells may test negative by immediate spin but positive by indirect antiglobulin test (IAT). Importantly, weak D types 1, 2, and 3 are not immunogenic and do not lead to anti-D formation (such individuals can be treated as RhD-positive safely). Little is known about the risk of making anti-D for most of the >150 other weak D types and therefore they are deemed RhD-negative for the purposes of RhIG antenatal prophylaxis.

The Partial D type refers to the collection of RhD variants with altered forms of the D antigen where some epitopes are missing. These individuals express most of the D protein, but not all of its antigenic parts making it possible for them to produce antibodies against the missing pieces. The best-known example is the DVI variant, historically associated with allo-anti-D formation.

Why Does this matter?

When a person with a partial D phenotype is typed as “RhD-positive” using routine serology, clinicians might wrongly assume they cannot make anti-D. If that person is exposed to the full D antigen, through pregnancy or transfusion, they can become alloimmunized and form clinically significant anti-D. An older term for this was that the patient was a D mosaic. The anti-D can cause hemolytic disease of the fetus and newborn (HDFN) in a subsequent pregnancy or a transfusion reaction. In fact, cases of partial D individuals forming anti-D are exactly why some countries have policies to treat certain patients as RhD-negative despite serologic Rh-positive results.

Modern anti-D reagents cannot always distinguish between weak D and partial D types. Some reagents may detect only certain epitopes and miss others entirely. This is especially problematic in diverse populations, where non-European RHD alleles are more prevalent and varied.

Molecular Genotyping

That’s where molecular genotyping comes in. By examining the DNA sequence of the RHD gene, genotyping can:

• Determine which specific weak or partial D allele is present.
• Distinguish between “safe” weak D types (e.g. weak D types 1, 2, 3, which don’t require RhIG) and those that should be managed as RhD-negative (e.g. DVI, certain partial D variants).
• Guide clinical decisions in obstetrics, transfusion, and donor labeling (for example, ensuring a mother with a partial D gets RhIG, or labeling a donor with a partial D as Rh-negative to protect recipients).

Regulatory agencies including AABB, CAP, and ISBT now recommend reflex genotyping in certain situations, especially for pregnant women with serologically weak D expression. This allows for safely withholding RhIG in those who truly don’t need it and appropriately administering it to those at risk of alloimmunization.

Some laboratories have built-in algorithms in their testing platforms or middleware to flag these cases. For example, patients with a weak D phenotype or with inconsistent results across different test methods can automatically trigger a reflex RHD genotyping to resolve their RhD status. In blood donors, some services have even begun labeling units based on molecular RHD typing to minimize the risk of alloimmunization in RhD-negative recipients.

The Takeaway?

Serology tells you what antigen phenotype is present on the cells and genotyping tells you which allele is behind it. In the case of RhD, that distinction can mean the difference between a safe pregnancy vs. alloimmune HDFN, or a compatible transfusion vs. an unexpected anti-D problem.

RhD typing is no longer a simple yes/no question. It’s a clinical story – one that genotyping helps us read with clarity and confidence.